J. P. Nadda discusses India's pharma leadership at an industry event.
India is positioning itself to become a global leader in advanced medicines, including biologics and biosimilars, according to Union Minister J P Nadda. Speaking at the India Pharma 2026 event, Nadda highlighted the need for increased research and investment to achieve this goal.
The government is actively supporting domestic manufacturing and self-reliance through initiatives like the Biopharma SHAKTI program and Production Linked Incentive (PLI) schemes. These policies are designed to strengthen India’s pharmaceutical sector and encourage innovation.
Nadda’s statements underscore the government’s commitment to fostering a robust pharmaceutical industry capable of competing on a global scale. The focus on biologics and biosimilars reflects a strategic move towards high-value segments of the market.
The success of these initiatives will depend on continued investment in research and development, as well as effective implementation of the government’s policies. If successful, India could significantly increase its presence in the global pharmaceutical market.
About the Author
